10559675 - GAU: 1626

Docket No. 130-PCT-US

IN THE UNITED STATE PATENT AND TRADE MARK OFFICE

Applicant: Serial No:

James Jaquith et al Not vet Assigned

Art unit:

Not yet assigned

Examiner:

Not vet assigned

Filed:

Customer No:

Title:

Acylated and Non-acylated Imidazo[2,1-b]-1,3,4-Thiadiazole-2-

Sulfonamides, and Uses Thereof

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, Virginia USA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This statement is being filed with the application. Applicants submit the enclosed PTO 1449 form identifying four (4) references. Under 35 USC § 120, this application relies on the earlier filing date of application serial number PCT-CA2004/000873 filed June 14, 2004.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Respectfully submitted.

Date: December 2, 2005.

Registration No: 55,978

Dr. Philip A. Swain c/o Aegera Therapeutics Inc 810 Chemin du Golf Nun's Island, Quebec Canada H3E 1A8 -

Telephone: (514) 288 - 4091 Ext: 353

Facsimile: (514) 288 - 9820

10559675 - GAU: 1626

10/5596**75** IAP9 Rec'd PCT/PTO 06_DEC_2005

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449/PTO			or a rese, no persone di	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Guosina	10 10 11 14 11 10			Application Number	PCT/CA2004/000873		
INF	DRMATION	DIS	CLOSURE	Filing Date			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	James Jaquith		
(Use as many sheets as necessary)				Art Unit			
				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	130-PCT-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.S./		ANDNAPPA, K, et al. Synthesis and biological evaluation(dimethylamino)meth. Arzneimittel Forshung, Drug Research, Editio Cantor, Aulendorf,De vol.49,no. 10:858-863.	
/K.S./		TALLEY, J.J. et al. "N-" (5-Methyl-3-phenylisoxaziol-4-yl)-phenyli.Journal of Medicinal Chemistry, American Chemical Society, Washington, US. vol 43, no.9, May 2000:1661-1663	
		-	
		·	

Examiner Signature	/Kamal Saeed/	Date Considered	03/01/2009			
*EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

considered. Include copy of this form with next communication to applicant.

Consideration include Copying designed with the Consideration of the Con amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10559675 - GAU: 1626

Substitute for form 1449/PTO

IAP9 Rec'd PCT/PTO

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

Application Number PCT/CA2004/000873 Filing Date INFORMATION DISCLOSURE First Named Inventor

James Jaquith STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Examiner Name Sheet 1 of 2 Attorney Docket Number 130-PCT-US

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (F known)}			Figures Appear
		US- ·			
		US-			
		US-			
		US-			
-		US-			
		US-	1		
		US-			
		US-			
		US-	+		
		US-	† · · · · · · · · · · · · · · · · · · ·		
-	_	US-			
	_	US-			,
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-		-	
		US-			
		US-	 		
		US-	 		
	_	US-	+		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)				
/K.S./		GB 1 464 259 A	09 02 1977	Pfizer Ltd		
/K.S./		WO 03/051590 A	06 26 2003	Aegera Therapeutics Inc		
						⊢
						Н
				1		H

Examiner Signature	/Kamal Saeed/	`	Date Considered	03/01/2009

"EXAMINES! Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's ineque citation designation number (optional). "See Kinds Codes of USPTO Patient Documents at https://www.uspic.gov or MPEP 90104. "Error fortion that issued the document, by the wheter code (WPO Standard ST.3). "For Japanese patient documents, the indication of the year of the reign of the Emperor must procede the serial number of the patient document. "Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.16 if yossible." "Applicant is to place a check mark feel English language." Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, or to the process, an approximation to demonstrating the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.